Epigenetic contributions to clinical risk prediction of cardiovascular disease

- 2 Aleksandra D Chybowska¹, Danni A Gadd¹, Yipeng Cheng¹, Elena Bernabeu¹, Archie
- 3 Campbell¹, Rosie M Walker², Andrew M McIntosh³, Nicola Wrobel⁴, Lee Murphy⁴, Paul
- 4 Welsh⁵, Naveed Sattar⁵, Jackie F Price⁶, Daniel L McCartney¹, Kathryn L Evans¹, Riccardo E
- 5 Marioni^{1,*}

1

6

- 7 Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer,
- 8 University of Edinburgh, EH4 2XU, UK.
- ⁹ School of Psychology, University of Exeter, Perry Road, Exeter, EX4 4QG, UK.
- ³ Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh,
- 11 EH10 5HF, UK.
- ⁴ Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital,
- 13 Edinburgh, EH4 2XU, UK.
- ⁵ Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research
- 15 Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
- ⁶ Usher Institute, University of Edinburgh, Old Medical School, Teviot Place, Edinburgh,
- 17 EH8 9AG, UK.

- 19 *Corresponding author:
- 20 Name: Riccardo Marioni
- 21 Contact Details: riccardo.marioni@ed.ac.uk

Abstract

1

2

4

5

6

7

8

9

11

12

13

14

15

16

18

19

20

21

22

23

24

Background and Aims

3 Cardiovascular disease (CVD) is among the leading causes of death worldwide. Discovery of

new omics biomarkers could help to improve risk stratification algorithms and expand our

understanding of molecular pathways contributing to the disease. Here, ASSIGN – a

cardiovascular risk prediction tool recommended for use in Scotland – was examined in tandem

with epigenetic and proteomic features in risk prediction models in ≥12,657 participants from

the Generation Scotland cohort.

Methods

10 Previously generated DNA methylation-derived epigenetic scores (EpiScores) for 109 protein

levels were considered, in addition to both measured levels and an EpiScore for cardiac

troponin I (cTnI). The associations between individual protein EpiScores and the CVD risk

were examined using Cox regression (n_{cases}≥1,274; n_{controls}≥11,383) and visualised in a tailored

R application. Splitting the cohort into independent training (n=6,880) and test (n=3,659)

subsets, a composite CVD EpiScore was then developed.

Results

17 Sixty-five protein EpiScores were associated with incident CVD independently of ASSIGN

and the measured concentration of cTnI (P<0.05), over a follow up of up to 16 years of

electronic health record linkage. The most significant EpiScores were for proteins involved in

metabolic, immune response and tissue development/regeneration pathways. A composite

CVD EpiScore (based on 45 protein EpiScores) was a significant predictor of CVD risk

independent of ASSIGN and the concentration of cTnI (Hazard Ratio HR=1.32, P=3.7x10⁻³,

0.3% increase in C-statistic).


Conclusions

- 1 EpiScores for circulating protein levels are associated with CVD risk independent of traditional
- 2 risk factors and may increase our understanding of the aetiology of the disease.

4 Keywords

ASSIGN, SCORE2, epigenetics, EpiScores, multi-omics, CVD prediction

Graphical abstract



Structural graphical abstract. ASSIGN – a cardiovascular risk prediction tool recommended for use in Scotland – was examined in tandem with epigenetic and proteomic features in risk prediction models in ≥12,657 participants from the Generation Scotland cohort. Cox regression was used to model the association between individual predictors and CVD hospitalisation events ascertained over 16 years of follow-up. Finally, a composite protein EpiScore was developed (based on the protein EpiScores) and its predictive performance was tested. CVD – Cardiovascular Disease, EpiScore – Epigenetic Score, Cox PH – Cox Proportional Hazards Regression, DNAm – DNA methylation.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Introduction For the past 20 years, cardiovascular disease (CVD) has been among the leading causes of mortality and morbidity worldwide. Given that many CVD cases are preventable, it is important to identify at-risk individuals early, when an intervention is most likely to be effective, and translate this knowledge into preventative strategies ^{1,2}. Although there are many CVD risk prediction algorithms, currently they have a limited predictive performance. It may be possible to improve on that by discovering novel factors strongly associated with the disease, for example the type and the concentrations of proteins expressed as a response to the damage of the cardiovascular system. An established and a highly sensitive marker of myocardial damage is cardiac troponin ³. It is a complex of three proteins, namely cardiac troponin I (cTnI), cardiac troponin T (cTnT), and cardiac troponin C (cTnC) regulating the contraction of the cardiac muscle. Cardiac forms of troponin T^{4,5} and I are expressed almost exclusively in the heart ⁶. Following myocyte damage, cardiac troponin enters the circulation and can be detected in blood samples. A high-sensitivity cardiac troponin test plays a role in a rapid diagnosis of myocardial infarction³. Low-grade elevations in cardiac troponin are associated with increased risk of CVD³. Individual differences in protein concentration can be well-captured by DNA methylation (DNAm). DNAm is a type of epigenetic modification characterised by the addition of methyl groups to DNA. Typically, the methyl group is added at cytosine-phosphate-guanine (CpG) dinucleotides, which are found mostly (but not exclusively) in gene promoters ⁷. Blocking promoters, to which activating transcription factors should bind in order to initiate transcription, is one of the mechanisms by which DNA methylation can precisely regulate gene expression 8.

DNAm-based proxies for protein levels are referred to as protein EpiScores and are broadly analogous to polygenic risk scores. These methylation scores can be derived from penalised linear regression models of protein concentrations. Due to their temporal stability, protein EpiScores may exhibit stronger associations with disease outcomes than singular protein measurements, which are known to fluctuate between measurements 9-12. We have shown that EpiScores for 109 circulating protein levels are associated with the time-to-diagnosis for a host of leading causes of morbidity and mortality, including cardiovascular outcomes 13. Protein EpiScores are therefore useful biomarker tools for disease risk stratification.

Here, we examine whether protein EpiScores, calculated for ≥12,657 participants of the Generation Scotland (GS), study can augment predictions made by a CVD risk calculator developed for use in Scotland (ASSIGN14). We first run individual Cox proportional hazards (PH) models to discover relationships between individual protein EpiScores and incident CVD. We then create a CVD EpiScore (based on the protein EpiScores) and test the additional predictive performance offered by it for CVD risk stratification.

Methods

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Generation Scotland (GS) Generation Scotland is a population-based and family-structured cohort study of individuals from Scotland ¹⁵. Between 2006 and 2010, patients at collaborating general medical practices in Scotland aged 35-65 years were invited to join the study. Subsequently, participants were asked to identify first-degree relatives aged 18 and over who were then invited to participate. 24,088 participants, aged 18-99 years, completed a health survey. Clinical and physical characteristics of 21,521 individuals who attended a clinic were measured using a standardized protocol. Fasting blood samples were obtained in clinic using a standard operating procedure. Measurement of high-sensitivity troponin The concentrations of high sensitivity cTnI (Abbott Diagnostics) were measured in 19,130 GS individuals. Before the assay, samples were spun for 5 minutes at 2000g. The measurements were taken using i1000SR and Cobas e411 devices using the manufacturers' quality controls and calibrators. The limit of detection set by manufacturers of these devices is 1.2 ng/L. Anything below this limit is reported as a blank value. Correcting for blank values consisted of reporting results below the threshold of blank as 0.6 ng/L³. **DNA Methylation** DNAm was profiled in blood samples using the Illumina EPIC array. Quality control details have been described previously ¹⁶. Filtering for poorly detected probes and samples, non-blood (e.g., saliva) samples and outliers was performed. Subsequently, non-CpG probes as well as probes on the X and Y chromosomes were removed. Missing CpG values were mean-imputed. To ensure any signatures generalise to as many cohorts as possible, the sites were subset to those also present on the older Illumina 450k array (n=453,093 CpGs). The full quality-

controlled dataset contained 18,413 individuals.

Methylation profiling was carried out in three sets. Set 1 contained 5,087 individuals, Set 2

contained 4,450 individuals and Set 3 contained 8,876 individuals. Participants in Set 2 were

genetically unrelated to each other and to those in Set 1 (genetic relationship matrix (GRM)

threshold <0.05) while more complex relationship structures were present within and between

Sets 1 and 3.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

The 109 protein EpiScores described by Gadd et al. 13 were projected into the cohort via the

publicly available MethylDetectR Shiny App ¹⁷. A short tutorial on MethylDetectR is available

at https://youtu.be/65Y2Rv-4tPU. Prior to calculating the scores, methylation level at each site

was scaled within set to have a mean of zero and standard deviation (SD) of one.

ASSIGN and SCORE2 scores

ASSIGN scores were calculated for 16,366 GS individuals with complete information about

the component parts (age, sex, smoking status, systolic blood pressure, total cholesterol, high

density lipoprotein cholesterol, family history of premature CVD, diagnosis of rheumatoid

arthritis, diagnosis of diabetes, and a deprivation score). Variables were adjusted as per official

guidance (FAQs - ASSIGN Score, 2022). This included modifying the number of cigarettes

smoked per day in recent quitters, adding 20mmHg to systolic blood pressure in individuals on

blood pressure medications, and adding 10 to the number of cigarettes smoked per day in

rheumatoid arthritis patients. The ASSIGN score was calculated in R using publicly available

coefficients and formulae ¹⁹. A subset of the obtained scores was validated against the scores

produced by the online tool ¹⁴.

1 SCORE2 values were calculated for 16,934 GS individuals using external coefficients ²⁰. The

estimates were calibrated according to region-specific scaling factors and validated against the

online tool 21. The R scripts used to derive ASSIGN and SCORE2 are available at

https://github.com/aleksandra-chybowska/troponin episcores.

Cardiovascular disease events

2

3

4

5

6

13

14

16

17

18

19

20

21

22

23

24

25

- 7 CVD cases were ascertained through data linkage to NHS Scotland hospital records.
- 8 Participants were followed to the end of September 2021. A composite CVD outcome was
- 9 defined as per Welsh et al. 3 and included the following International Classification of
- 10 Diseases, 10th Revision codes: I20–25, G45, I60–69, I00–I99, L29.5, L31.1, K40–46, K49,
- 11 K75. A total of 2,265 incident CVD cases were observed over a follow up period of up to 16
- 12 years (Supplementary Figure 1).

Statistical analysis for risk associations

15 Cox proportional hazards (PH) models were used to investigate the relationship between the

CVD outcome and the following potential biomarkers: measured cardiac troponin, troponin

EpiScores, and 109 protein EpiScores. All models were adjusted for ASSIGN. Protein

EpiScore models were additionally adjusted for the corrected concentration of cTnI (see

Methods - Measurement of high-sensitivity troponin). The levels of protein EpiScores as

well as troponin concentrations were rank-based inverse normalised prior to the analyses. CVD

cases comprised individuals diagnosed after baseline who subsequently died as well as of those

who remained alive after receiving a diagnosis. Controls were censored at the end of the follow

up period (September 2021) or at time of death (CVD-free survival). Models based on data

from merged Sets 1, 2, and 3 were generated using coxme library (v 2.2.16) with a kinship

matrix fitted as a random effect to adjust for relatedness. Cox model assumptions were checked

by running the cox.zph function from the survival library (v. 3.2.7) 22 was used to examine 1 2 Schoenfeld residuals (local and global tests with significance threshold P< 0.05). These models 3 were not adjusted for relatedness. Survival, forest, and hazard-over-time plots were generated 4 using shiny application available custom at a 5 https://shiny.igc.ed.ac.uk/3d2c8245001b4e67875ddf2ee3fcbad2/. 6 7 **Composite CVD EpiScore** 8 An epigenetics-based CVD score referred to as the CVD EpiScore was generated. It considered 9 the 109 DNAm scores reflecting the concentrations of plasma proteins (protein EpiScores) from Gadd et al 13 as potentially informative features (n_{training}=6,880, n_{test}=3,659, 10 11 **Supplementary Figure 2**). The score was derived using two different modelling techniques: 12 Cox PH Elastic Net and Random Survival Forest. While Elastic Net models were trained using glmnet (v 4.0.2) ²³, Random Survival Forest models were trained using randomForestSRC (v 13 14 3.2.0). Protein EpiScores were rank-based inverse normalised prior to training. 15 Elastic Net models were trained with the L1-L2 mixing parameter set to alpha=0.5 and with 16 ten-fold cross-validation. The features with non-zero coefficients were used to generate 17 composite score. Random Forest models were trained using ten-fold cross-validation. The 10-18 year onset probabilities were calculated and used as a composite CVD EpiScore. 19 20 Finally, to test whether the CVD EpiScore improved prediction of CVD over and above 21 ASSIGN, the following Cox PH models were fit to the test set: a null model adjusted for age, 22 sex, and ASSIGN, then full models, which included age, sex, ASSIGN score and 1) the CVD EpiScore, 2) the concentration of rank-based inverse normalised cTnI and 3) the CVD EpiScore 23 24 + the concentration of cTnI.

- 1 Evaluating Performance of the Composite Scores
- 2 Cox PH analysis can be used model the risk of incident CVD for different prediction periods.
- 3 As the ASSIGN score estimates the risk of developing CVD over 10 years, we used 10-year
- 4 CVD incidence to evaluate the classification performance of our models. To calculate the
- 5 binary CVD outcome, time-to-event was truncated at 10-years. Prediction probabilities were
- 6 obtained in the test set for each model by calculating the cumulative baseline hazard using the
- 7 Breslow estimator ²⁴. Prediction metrics (Area Under the receiver operator characteristic Curve
- 8 (AUC), Precision-Recall AUC and C-index) were then generated using the pROC package ²⁵.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Results Clinical risk prediction tools ASSIGN scores were calculated for 16,366 individuals with non-missing risk factor data. To meet the proportional hazards assumption of the Cox model, the dataset was filtered to individuals between 30 and 70 years old (results split by decade are presented in **Supplementary Table 1)** and trimmed of outliers (points beyond 3 SDs of the mean, n=181). This left a cohort of 12,790 individuals, which was further filtered to records with non-missing concentrations of cTnI (n = 12,657). Table 1 summarises the training, test, and full datasets. We observed that ASSIGN risk scores were strongly positively correlated with estimates produced by SCORE2 – an algorithm validated to predict 10-year CVD risk in European populations. In a sample of GS individuals within the recommended SCORE2 age range (40-69 years old, n=11,348), the Spearman's correlation coefficient of ASSIGN and SCORE2 was 0.89 (Supplementary Figure 3). Given that the ASSIGN score was tailored to Scottish population, we decided to use it as the primary CVD risk measure, with SCORE2 used in sensitivity analyses. Incremental model using cardiac troponin and cardiac troponin EpiScores We tested whether concentrations of cardiac troponin were associated with CVD risk over and above ASSIGN. While measured concentration of cTnI was associated with an HR of 1.20 per SD increase (95% CI 1.13, 1.29; P=1.9x10⁻⁸), an EpiScore generated for cTnI (see Supplementary Methods for details) was weakly associated with the measured concentrations (incremental R²=0.10%, P=0.03) and did not predict CVD risk in Cox models adjusted for ASSIGN (P=0.97). For that reason, it was not considered as a feature in the generation of the composite CVD score.

- 1 Table 1. Summary of training, test, and full datasets. For continuous variables with normal distributions, summary values are reported as mean
- 2 (SD). Median [Q1, Q3] are given for continuous variables which do not follow a normal distribution. A number and a percentage of samples are
- 3 reported for categorical variables. SIMD Scottish Index of Multiple Deprivation, CHD Coronary Heart Disease.

	Tra	ining	To	est	Fu	ıll
	Cases	Controls	Cases	Controls	Cases	Controls
n	658	6222	337	3322	1274	11383
Time-to-event	7.0	11.8	4.8	11.8	6.8	11.8
(Years to Onset or Censoring)	[4.1, 9.9]	[11.1, 13.0]	[2.6, 7.6]	[11.0, 13.6]	[3.7, 9.8]	[11.1, 13.2]
Ago (Voors)	58.3	50.0	56.6	51.5	57.4	50.4
Age (Years)	[50.8, 62.6]	[40.8, 58.8]	[51.6, 60.0]	[43.9, 57.6]	[51.0, 62.2]	[41.5, 58.2]
Sov (Mole)	345	2452	165	1219	655	4399
Sex (Male)	(52.4%)	(39.4%)	(49.0%)	(36.7%)	(51.4%)	(38.6%)
SIMD (score/10)	41.6	45.3	45.1	44.5	41.8	44.9
SIMD (score/10)	[22.2, 53.3]	[26.3, 55.1]	[20.2, 54.9]	[22.6, 54.8]	[21.6, 54.0]	[25.5, 54.9]
Family history of CHD/Stroke (Yes)	443	3171	224	1781	862	5881
Family instory of CHD/Stroke (1es)	(67.3%)	(51.0%)	(66.5%)	(53.6%)	(67.7%)	(51.7%)
Diabetes (Yes)	19	63	16	72	43	165
Diabetes (Tes)	(2.9%)	(1.0%)	(4.7%)	(2.2%)	(3.4%)	(1.4%)
Rheumatoid arthritis (Yes)	29	140	23	110	71	281
Kileumatolu ai tiii itis (1 es)	(4.4%)	(2.3%)	(6.8%)	(3.3%)	(5.6%)	(2.5%)
Non-smoker (Yes)	534	5306	280	2752	1044	9623
TVOII-SHIOKEI (1 es)	(81.2%)	(85.3%)	(83.1%)	(82.8%)	(81.9%)	(84.5%)
Systolic blood pressure (mmHg)	142.1	130.8	140.3	130.3	141.5	130.6
Systone blood pressure (mining)	(16.7)	(16.9)	(17.6)	(16.5)	(17.2)	(16.8)
Total cholesterol (mmol/l)	5.4	5.2	5.3	5.3	5.4	5.2
Total choicster of (minor)	(1.1)	(1.0)	(1.1)	(1.1)	(1.1)	(1.0)
HDL cholesterol (mmol/l)	1.3	1.4	1.4	1.5	1.3	1.4
TIDE CHOICSTEIO (IIIIIIO)/I)	[1.1, 1.6]	[1.2, 1.7]	[1.1, 1.6]	[1.2, 1.8]	[1.1, 1.6]	[1.2, 1.7]
ASSIGN score	19	9	18	10	18	9
ASSIGN SCORE	[12, 29]	[4, 18]	[11, 28]	[5, 17]	[11, 28]	[4, 17]

1 Incremental model using EpiScores for plasma protein levels 2 We then tested whether 109 protein EpiScores generated by Gadd et al. (protein description available in Supplementary Table 2)¹³ were associated with CVD risk over 16 years of 3 4 follow-up. 5 6 Firstly, we generated 109 Cox PH CVD risk models adjusted for ASSIGN. Each model was 7 additionally adjusted for a different protein EpiScore. Eight EpiScores failed to satisfy the 8 proportional hazards assumption (Schoenfeld residual test P>0.05). Of the remaining 101 9 protein EpiScores, 67 were significantly associated with CVD risk (P<0.05). After applying a 10 conservative Bonferroni threshold for multiple testing ($P < 0.05/101 = 5.0 \times 10^{-4}$), 36 associations 11 remained statistically significant. 12 Secondly, to understand whether protein EpiScores were associated with CVD risk beyond 13 14 established biomarkers such as cardiac troponin, we included the concentration of cTnI as a 15 covariate in the model along with ASSIGN and we repeated the analysis. Of the 101 16 aforementioned protein EpiScores, 65 associated with CVD over and above the ASSIGN score 17 and the concentration of cTnI (P<0.05, Figure 1). 33 associations remained significant after 18 correcting for multiple testing. 19




Figure 1. Associations between protein EpiScores and incident CVD. Hazard ratios are plotted for the 67 significant associations (P<0.05) with 95% confidence interval limits. Basic models were adjusted for ASSIGN (blue), whereas full models included the ASSIGN score and concentration of cTnI as covariates (red).


- 1 In models adjusted for ASSIGN and the concentration of cTnI, higher levels of 41 protein
- 2 EpiScores were associated with an increased hazard of CVD (HR>1 and P<0.05). For example,
- 3 elevated levels of CRP and MMP12 were associated with HR of 1.23 (95% CI 1.16, 1.30;
- 4 P= 9.2×10^{-12}) and 1.13 (95% CI 1.06, 1.22, P= 5.4×10^{-4}) (**Figure 2, A**), respectively. In contrast,
- 5 higher levels of 24 protein EpiScores were associated with a decreased hazard of CVD (HR<1
- and P<0.05). Examples of protein EpiScores belonging to this group include *NOTCH1* (HR per
- 7 SD of 0.84, 95% CI 0.79, 0.89; $P=1.6\times10^{-9}$) and *OMD* (HR per SD of 0.87, 95% CI 0.82, 0.92;
- 8 P=1.0x10⁻⁶). The relationships between individual EpiScores and CVD risk have been
- 9 visualised in a form of risk-over-time (Figure 2, B), forest, and Kaplan Meier plots in an online
- R application: https://shiny.igc.ed.ac.uk/3d2c8245001b4e67875ddf2ee3fcbad2/.

1 A. MMP12

Year

Cases

Controls



3 B. OMD 1.00 1.00 1.00 1.00 1.00 1.00 0.95 0.85 0.80 0.75

12536 12446 12328 12243 12123 12013 11898 11787 11672 11581 11535 11510 11504 11502

Figure 2. Changes in CVD free survival (A) and CVD risk (B) plotted for two selected protein EpiScores. A. Individuals with higher levels of MMP12 (>75th percentile) had shorter CVD free survival when compared to those with higher level of this EpiScore (<25th percentile). B. Hazard ratios (HR) and 95% confidence intervals associated with the levels of OMD EpiScore plotted over time. At all examined time points the association with CVD risk was significant (P<0.05).

- 1 Finally, to learn whether individual protein EpiScore can augment CVD prediction beyond
- 2 established biomarkers and clinical risk prediction tools, we calculated C-statistics for null and
- 3 full models. While the null model was adjusted for ASSIGN and the concentration of cTnI (C-
- 4 stat=0.728), the full model also contained the studied protein EpiScore. **Table 2** lists top 10
- 5 associations that result in the greatest improvement of CVD risk prediction.

7

Table 2. C-statistics calculated for null and full protein EpiScore models. Risk was ascertained over 16 years of follow-up. The null model was adjusted for ASSIGN and the concentration of cardiac troponin I, while the full model also included a studied EpiScore.

EpiScore	C _{full} -C _{null}	Function
IGFBP4	0.0050	Metabolic / Growth promoter
CRP	0.0050	Immune response
NTRK3	0.0046	Neural development / Cell signalling
FGF21	0.0042	Metabolic
CSF3	0.0039	Immune response
HGF	0.0035	Growth factor / tissue regeneration
ACVRL1	0.0035	Vascular
CNTN4	0.0035	Cell adhesion / maintenance
PIGR	0.0034	Immune response
RARRES2	0.0032	Metabolic

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Composite Episcore for CVD- risk prediction To understand whether the above-mentioned protein EpiScores can be used as biomarkers that add additional predictive value over-and-above typically used clinical risk scores (ASSIGN and SCORE2) and the concentration of cTnI, we generated a composite CVD EpiScore – a weighted linear combination of individual protein EpiScores. The score was trained using two modelling techniques: Cox PH Elastic Net and Random Survival Forest. There were 6,880 records in the training set and 3,659 records in the test set. The Elastic Net assigned non-zero coefficients to 45 of 109 protein EpiScores (Supplementary Table 3). In 10-year Elastic Net prediction analysis, the null model (containing age, sex, and ASSIGN) had an AUC of 0.719. The model with the CVD EpiScore increased the AUC to 0.723. The addition of cTnI to the null model resulted in an AUC of 0.721. The full model (null model + cTnI + CVD EpiScore) AUC was 0.724. Full output for the CVD models including C-statistics and a comparison with SCORE2 can be found in **Supplementary Table 4** and **Supplementary** Table 5. The CVD EpiScore remained statistically significant after adjusting for the concentration of cTnI in models incorporating ASSIGN and SCORE2 (HR=1.32, P=3.7x10⁻³ and HR=1.36, P= $1.4x10^{-3}$, respectively). Random Survival Forest-based analysis (see Methods) yielded similar results. The null model (as above) had an AUC of 0.719. Adding the CVD EpiScore to the null model increased the AUC to 0.721. The full model adjusted for CVD EpiScore and the concentration of cardiac troponin had an AUC of 0.723.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Discussion In this study, we describe 65 novel epigenetic biomarkers that associate with long-term risk of CVD independently of a clinical risk prediction tool (ASSIGN) and the concentration of an established protein biomarker (cTnI). The most statistically significant EpiScores reflected concentrations of proteins involved in metabolic, immune, and developmental pathways. A weighted linear combination of protein EpiScores (the composite protein CVD EpiScore) was significantly associated with CVD risk in models adjusted for ASSIGN. Although the score may be a useful addition to other omic features in future CVD risk prediction tools, at present it is unlikely to be measured in a clinical setting ²⁶. One previous study focused on how DNAm biomarkers improve CVD risk prediction ²⁷. Using time-to-event data and a panel of 60 blood DNAm biomarkers measured in an Italian cohort of 1803 individuals (295 cases), Cappozzo et al. trained a composite score for predicting shortterm risk of CVD. In comparison, we focused on a more extensive panel of DNAm protein markers in addition to measured troponin levels. We also ran univariate analyses to identify individual proteins and protein classes that associate with CVD. Furthermore, we developed 10-year prediction models (the prediction window for which both ASSIGN and SCORE2 are recommended) trained on more than double the number of cases. Our findings suggest that individual protein EpiScores capture disease-specific biomarker signals relevant to CVD risk prediction. The relationships found between 65 protein EpiScores and incident CVD mirrored previously reported associations between CVD and measured protein concentrations. For example, elevated levels of CRP, a marker for systemic low-grade inflammation, have been associated with multiple age-related morbidities, including CVD ²⁸. MMP12 and OMD, in turn, are involved in maintaining the stability of atherosclerotic plaques.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

While MMP12 contributes to the growth and destabilisation of plaques ²⁹, increased levels of OMD have been observed in macro-calcified plaques from asymptomatic patients ³⁰. Finally, multiple studies have demonstrated that NOTCH1 signalling protects the heart from CVDinduced myocardial damage. The Notch1 pathway is involved in neo-angiogenesis and revascularisation of failing heart ³¹. It limits the extent of ischemic injury ³¹, reduces fibrosis ³² and improves cardiac function ³³. Several of the protein EpiScores associated with CVD in our study, such as SELE and C5, have also been shown to associate with stroke and ischemic heart disease in our previous work ¹³. In contrast, the protein EpiScore we trained for cTnI was not associated with the incidence of CVD. Therefore, we excluded it from composite CVD score generation. This highlights an important consideration in the development of multi-omics biomarkers, as there are unlikely to be DNAm differences that associate with every blood protein. For example, the 109 protein EpiScores generated by Gadd et al that we make use of in our study were extracted as the bestperforming EpiScores from a total set of 953 proteins tested as potential outcomes ¹³. It is therefore not always possible to generate a meaningful protein EpiScore that reflects the protein biology. In the case of cardiac troponins, the elevations in circulating cTnI and cTnT are a result of a leakage of these proteins from the damaged heart muscle into the bloodstream ³⁴. As opposed to transcription, this process is not regulated by DNA methylation. Therefore, the methylation signal underlying increased concentration of cardiac troponin in the bloodstream may too weak to enable generation of a meaningful EpiScore. Strengths of this study include the precise timing of the CVD event through the electronic health records, the ability to generate a clinical risk predictor in a population cohort, and the

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

very large sample size for DNAm, which also permitted the splitting of the data into train/test sets to formally examine the improvement in risk prediction from our omics biomarkers. Limitations to this work include the generalisability beyond a Scottish population. In this study, we trained and tested predictors in a Scottish cohort to augment the ASSIGN score. However, many of the protein EpiScores were trained in a German cohort (KORA) and projected to Generation Scotland ¹³. Although the ASSIGN score is tailored to the Scottish population, we observed similar findings across all models when replacing it with SCORE2, which is widely used across Europe. In conclusion, we identified novel epigenetic signals that were associated with the incidence of CVD independently of ASSIGN and the concentration of cardiac troponin. The exploration of associations between protein EpiScores and CVD shed light on the aetiology and molecular biology of the disease. As DNAm and proteins are assessed in increasingly large cohort samples, it will be possible to evaluate more precisely the potential gains in risk prediction, disease prevention and any associated health economic benefits. Acknowledgements We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. We would also like to thank Dr Robert Hillary for helpful feedback on the manuscript and analyses.

1 **Funding** 2 This research was funded in whole, or in part, by the Wellcome Trust (104036/Z/14/Z, 3 108890/Z/15/Z, 220857/Z/20/Z, and 216767/Z/19/Z). For the purpose of open access, the 4 author has applied a CC BY public copyright licence to any Author Accepted Manuscript 5 version arising from this submission. A.D.C is supported by a Medical Research Council PhD 6 Studentship in Precision Medicine with funding by the Medical Research Council Doctoral 7 Training Programme and the University of Edinburgh College of Medicine and Veterinary 8 Medicine. 9 D.A.G. is funded by the Wellcome Trust 4-year PhD in Translational Neuroscience-training 10 the next generation of basic neuroscientists to embrace clinical research (108890/Z/15/Z). 11 E.B. and R.E.M. are supported by the Alzheimer's Society major project grant AS-PG-19b-12 010. Generation Scotland received core support from the Chief Scientist Office of the Scottish 13 14 Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). 15 Genotyping and DNA methylation profiling of the GS samples was carried out by the Genetics 16 Core Laboratory at the Clinical Research Facility, University of Edinburgh, Scotland and was 17 funded by the Medical Research Council UK and the Wellcome Trust (Reference 18 104036/Z/14/Z, 220857/Z/20/Z, and 216767/Z/19/Z). The DNA methylation profiling and 19 analysis was supported by Wellcome Investigator Award 220857/Z/20/Z and Grant 20 104036/Z/14/Z (PI: AM McIntosh) and through funding from NARSAD (Ref: 27404; awardee: 21 Dr DM Howard) and the Royal College of Physicians of Edinburgh (Sim Fellowship; Awardee: 22 Dr HC Whalley). All components of GS:SFHS, including the protocol and written study 23 materials, have received formal, national ethical approval from NHS Tayside Research Ethics

Committee (REC reference number 05/S1401/89). In addition local approval has been obtained

- 1 from NHS Glasgow Research Ethics Committee, and from NHS Glasgow and NHS Tayside
- 2 Research and Development Offices, as is required.

Author contributions

3

4

- 5 R.E.M., and A.D.C. were responsible for the conception and design of the study. A.D.C carried
- 6 out the data analyses. D.A.G, Y.C and E.B. contributed to the analyses and methodology.
- 7 R.E.M. and A.D.C. drafted the article. A.C. facilitated data linkage. K.L.E. and J.F.P. were
- 8 involved in conceptualisation and provided consultation on the methodology. S.W.M.,
- 9 R.M.W., N.W., L.M., C.S., A.W.M., K.L.E contributed to data collection and preparation. All
- authors read and approved the final manuscript.

Conflict of interest

1

5

6

17

- 2 R.E.M. and L.M. have received a speaker fee from Illumina. R.E.M. is an advisor to the
- 3 Epigenetic Clock Development Foundation. D.A.G. and R.E.M. have received consultancy
- 4 fees from Optima partners. All other authors declare no competing interests.

Data availability

- 7 All code used in the analyses is available with open access at the following Gitlab repository:
- 8 https://github.com/aleksandra-chybowska/troponin episcores. The source datasets analysed
- 9 during the current study are not publicly available due to them containing information that
- 10 could compromise participant consent and confidentiality. Data can be obtained from the data
- 11 owners. Instructions for accessing Generation Scotland data can be found here:
- 12 https://www.ed.ac.uk/generation-scotland/for-researchers/access; the 'GS Access Request
- 13 Form' can be downloaded from this site. Completed request forms must be sent to
- access@generationscotland.org to be approved by the Generation Scotland access committee.
- Videos introducing the 109 protein EpiScores and MethylDetectR application are available at
- 16 https://www.youtube.com/channel/UCxQrFFTIItF25YKfJTXuumQ.

References

1

- 3 1. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk
- 4 prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort
- 5 study. BMJ 2017;357:j2099. doi:10.1136/bmj.j2099.
- 6 2. Staa T-P van, Gulliford M, Ng ES-W, Goldacre B, Smeeth L. Prediction of
- 7 Cardiovascular Risk Using Framingham, ASSIGN and QRISK2: How Well Do They
- 8 Predict Individual Rather than Population Risk? PLOS ONE 2014;9:e106455.
- 9 doi:10.1371/journal.pone.0106455.
- 10 3. Welsh P, Preiss D, Hayward C, Shah ASV, McAllister D, Briggs A, et al. Cardiac
- 11 Troponin T and Troponin I in the General Population. Circulation 2019;139:2754–2764.
- 12 doi:10.1161/CIRCULATIONAHA.118.038529.
- 4. Fridén V, Starnberg K, Muslimovic A, Ricksten S-E, Bjurman C, Forsgard N, et al.
- 14 Clearance of cardiac troponin T with and without kidney function. Clinical Biochemistry
- 15 2017;50:468–474. doi:10.1016/j.clinbiochem.2017.02.007.
- 16 5. Michielsen ECHJ, Wodzig WKWH, Van Dieijen-Visser MP. Cardiac Troponin T
- 17 Release after Prolonged Strenuous Exercise. Sports Med 2008;38:425–435.
- 18 doi:10.2165/00007256-200838050-00005.
- 19 6. Wu AHB. Release of cardiac troponin from healthy and damaged myocardium. Frontiers
- 20 in Laboratory Medicine 2017;1:144–150. doi:10.1016/j.flm.2017.09.003.
- 21 7. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes &
- Development 2011;25:1010. doi:10.1101/gad.2037511.
- 23 8. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from
- 24 epigenomics. Nat Rev Genet 2008;9:465–476. doi:10.1038/nrg2341.

- 9. Moldoveanu AI, Shephard RJ, Shek PN. Exercise elevates plasma levels but not gene
- 2 expression of IL-1β, IL-6, and TNF-α in blood mononuclear cells. Journal of Applied
- 3 Physiology 2000;89:1499–1504. doi:10.1152/jappl.2000.89.4.1499.
- 4 10. Koenig W, Sund M, Fröhlich M, Löwel H, Hutchinson WL, Pepys MB. Refinement of
- 5 the Association of Serum C-reactive Protein Concentration and Coronary Heart Disease
- Risk by Correction for Within-Subject Variation over Time: The MONICA Augsburg
- 7 Studies, 1984 and 1987. American Journal of Epidemiology 2003;158:357–364.
- 8 doi:10.1093/aje/kwg135.
- 9 11. Liu Y, Buil A, Collins BC, Gillet LCJ, Blum LC, Cheng L-Y, et al. Quantitative
- variability of 342 plasma proteins in a human twin population. Mol Syst Biol
- 11 2015;11:786. doi:10.15252/msb.20145728.
- 12. Stevenson AJ, McCartney DL, Hillary RF, Campbell A, Morris SW, Bermingham ML, et
- al. Characterisation of an inflammation-related epigenetic score and its association with
- 14 cognitive ability. Clinical Epigenetics 2020;12:113. doi:10.1186/s13148-020-00903-8.
- 13. Gadd DA, Hillary RF, McCartney DL, Zaghlool SB, Stevenson AJ, Cheng Y, et al.
- 16 Epigenetic scores for the circulating proteome as tools for disease prediction. ELife
- 17 2022;11:e71802. doi:10.7554/eLife.71802.
- 18 14. Estimate the risk ASSIGN Score 2022. https://www.assign-score.com/estimate-the-
- risk/visitors/ (accessed April 14, 2022).
- 20 15. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. Cohort
- 21 Profile: Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its
- participants and their potential for genetic research on health and illness. International
- 23 Journal of Epidemiology 2013;42:689–700. doi:10.1093/ije/dys084.
- 24 16. Cheng Y, Gadd DA, Gieger C, Monterrubio-Gómez K, Zhang Y, Berta I, et al.
- Development and validation of DNA Methylation scores in two European cohorts

- augment 10-year risk prediction of type 2 diabetes 2022:2021.11.19.21266469.
- 2 doi:10.1101/2021.11.19.21266469.
- 3 17. Hillary RF, Marioni RE. MethylDetectR: a software for methylation-based health
- 4 profiling. Wellcome Open Res 2020;5:283. doi:10.12688/wellcomeopenres.16458.2.
- 5 18. Faqs ASSIGN Score 2022. https://www.assign-score.com/faqs/ (accessed April 14,
- 6 2022).
- 7 19. Woodward M, Brindle P, Tunstall-Pedoe H, for the SIGN group on risk estimation*.
- 8 Adding social deprivation and family history to cardiovascular risk assessment: the
- 9 ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart
- 10 2005;93:172–176. doi:10.1136/hrt.2006.108167.
- 20. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk
- prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in
- Europe. European Heart Journal 2021;42:2439–2454. doi:10.1093/eurheartj/ehab309.
- 14 21. SCORE2 risk calculator for low-risk regions 2022.
- 15 https://heartscore.escardio.org/Calculate/quickcalculator.aspx?model=low (accessed
- 16 October 6, 2022).
- 17 22. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New
- 18 York: Springer; 2000.
- 19 23. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear
- Models via Coordinate Descent. Journal of Statistical Software 2010;33:1–22.
- 21 doi:10.18637/jss.v033.i01.
- 22 24. Lin DY. On the Breslow estimator. Lifetime Data Anal 2007;13:471–480.
- 23 doi:10.1007/s10985-007-9048-y.

- 1 25. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al. pROC: an open-
- 2 source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics
- 3 2011;12:77. doi:10.1186/1471-2105-12-77.
- 4 26. Wagner W. How to Translate DNA Methylation Biomarkers Into Clinical Practice.
- 5 Frontiers in Cell and Developmental Biology 2022;10.
- 6 27. Cappozzo A, McCrory C, Robinson O, Freni Sterrantino A, Sacerdote C, Krogh V, et al.
- A blood DNA methylation biomarker for predicting short-term risk of cardiovascular
- 8 events. Clinical Epigenetics 2022;14:121. doi:10.1186/s13148-022-01341-4.
- 9 28. Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FLJ, et al.
- 10 Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality
- in patients with type 2 diabetes. Cardiovascular Diabetology 2021;20:220.
- doi:10.1186/s12933-021-01409-0.
- 13 29. Goncalves I, Bengtsson E, Colhoun HM, Shore AC, Palombo C, Natali A, et al. Elevated
- 14 Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and
- 15 Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. Arteriosclerosis,
- Thrombosis, and Vascular Biology 2015;35:1723–1731.
- 17 doi:10.1161/ATVBAHA.115.305631.
- 30. Gonçalves I, Oduor L, Matthes F, Rakem N, Meryn J, Skenteris N-T, et al. Osteomodulin
- 19 Gene Expression Is Associated With Plaque Calcification, Stability, and Fewer
- 20 Cardiovascular Events in the CPIP Cohort. Stroke 2022;53:e79–e84.
- 21 doi:10.1161/STROKEAHA.121.037223.
- 22 31. Li Y, Hiroi Y, Ngoy S, Okamoto R, Noma K, Wang C-Y, et al. Notch1 in Bone Marrow–
- 23 Derived Cells Mediates Cardiac Repair After Myocardial Infarction. Circulation
- 24 2011;123:866–876. doi:10.1161/CIRCULATIONAHA.110.947531.


- 1 32. Ferrari R, Rizzo P. The Notch pathway: a novel target for myocardial remodelling
- therapy? European Heart Journal 2014;35:2140–2145. doi:10.1093/eurheartj/ehu244.
- 3 33. Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, et al. Activation of
- 4 Notch-Mediated Protective Signaling in the Myocardium. Circulation Research
- 5 2008;102:1025–1035. doi:10.1161/CIRCRESAHA.107.164749.

- 6 34. Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial
- 7 infarction: review of the current findings. Vasc Health Risk Manag 2010;6:691–699.


1 Supplement

2


3



Supplementary Figure 1. Pre-processing of the full dataset. This pipeline was used to prepare data for Cox PH models aimed at the identification of potential predictors of CVD. *Outlier threshold – an ASSIGN value that is more than 3 SD from the mean. Created with BioRender.com.



Supplementary Figure 2. Pre-processing of the training and test sets. While Set 1 was the test set, the training set consisted of Sets 2 and 3 combined. Pre-processing phenotypes (ASSIGN components, composite CVD event status and time-to-event) consisted of filtering out records with time-to-event≤0, removing records with a missing ASSIGN score, thresholding age of participants to 30-70 years and removing outliers (ASSIGN value that is more than 3 SD from the mean). To ensure that there were no individuals with overlapping family ids across the training and the test set, any individuals in the training set associated with the same family id as individuals from the test set were excluded from further analyses. Created with BioRender.com.



Supplementary Figure 3. Strongly correlated 10-year CVD risk estimates produced by ASSIGN and SCORE2.

Supplementary Table 1. Hazard ratio (HR) of ASSIGN estimated by Cox proportional hazards CVD model adjusted for relatedness using kinship matrix where the ASSIGN score is the only predictor.

Age category	HRASSIGN	95% CI	P _{ASSIGN}	ncases	N controls
<30	2.42	[1.43, 4.10]	9.4 x 10 ⁻⁴	20	2560
30 - 40	1.87	[1.48, 2.37]	2.0×10^{-7}	64	2436
40 - 50	1.97	[1.74, 2.22]	<2.2 x 10 ⁻¹⁶	232	3153
50 - 60	1.67	[1.55, 1.81]	$< 2.2 \times 10^{-16}$	526	3763
60 - 70	1.54	[1.42, 1.67]	<2.2 x 10 ⁻¹⁶	530	2267
≥70	1.27	[1.12, 1.44]	2.3×10^{-4}	252	551

1

Supplementary Table 2. Description of the 109 proteins for which Gadd et al. generated robust EpiScores. Table adapted from Gadd et. al 13 .

Identifier	(SOMAscan
------------	-----------

identifier (SOMASCAN			_
SeqId or Olink name)	Protein Panel	Gene Name	Target
4407-10	SomaScan	MST1	MSP
4435-66	SomaScan	ENPP7	ENPP7
4148-49	SomaScan	PAPPA	PAPP-A
3617-80	SomaScan	HGFAC	HGFA
3440-7	SomaScan	GZMA	granzyme A
3403-1	SomaScan	TPSB2	TPSB2
3291-30	SomaScan	FCER2	CD23
3195-50	SomaScan	GNLY	Granulysin
5124-69	SomaScan	ICAM5	sICAM-5
3216-2	SomaScan	PIGR	PIGR
5339-49	SomaScan	S100A9	calgranulin B
3175-51	SomaScan	ADAMTS13	ATS13
3311-27	SomaScan	FCGR3B	FCG3B
4500-50	SomaScan	CLEC11A	SCGF-alpha
2948-58	SomaScan	GHR	Growth hormone receptor
<i>2950-57</i>	SomaScan	IGFBP4	IGFBP-4
2966-65	SomaScan	CLEC11A	SCGF-beta
4337-49	SomaScan	CRP	CRP
2579-17	SomaScan	MMP9	MMP-9
4498-62	SomaScan	NCAM1	NCAM-120
3184-25	SomaScan	F7	Coagulation Factor VII
3324-51	SomaScan	LY9	LY9
5034-79	SomaScan	PRSS2	Trypsin 2
3343-1	SomaScan	ACY1	Aminoacylase-1
5358-3	SomaScan	OMD	OMD
3046-31	SomaScan	RETN	resistin
4568-17	SomaScan	SLITRK5	SLIK5
3448-13	SomaScan	INSR	IR
5028-59	SomaScan	CD163	sCD163
2658-27	SomaScan	NTRK3	TrkC
3292-75	SomaScan	CD48	CD48
4929-55	SomaScan	SHBG	SHBG
4924-32	SomaScan	MMP1	MMP-1
2580-83	SomaScan	MPO	Myeloperoxidase
4831-4	SomaScan	SELL	sL-Selectin

3152-57	SomaScan	TNFRSF1B	TNF sR-II
<i>2967-8</i>	SomaScan	VCAM1	VCAM-1
<i>5000-52</i>	SomaScan	LGALS3BP	LG3BP
3038-9	SomaScan	CXCL11	I-TAC
3169-70	SomaScan	IDUA	IDUA
<i>3060-43</i>	SomaScan	C9	C9
2665-26	SomaScan	TNFRSF17	BCMA
<i>2516-57</i>	SomaScan	CCL21	6Ckine
<i>2780-35</i>	SomaScan	LTF	Lactoferrin
4763-31	SomaScan	AFM	Afamin
3485-28	SomaScan	B2M	b2-Microglobulin
<i>2771-35</i>	SomaScan	IGFBP1	IGFBP-1
4481-34	SomaScan	C4A C4B	C4
<i>3505-6</i>	SomaScan	LTA LTB	Lymphotoxin a1/b2
<i>3041-55</i>	SomaScan	MRC2	MRC2
<i>3470-1</i>	SomaScan	SELE	sE-Selectin
3554-24	SomaScan	ADIPOQ	Adiponectin
<i>4990-87</i>	SomaScan	GP1BA	GP1BA
4920-10	SomaScan	LYZ	Lysozyme
<i>2851-63</i>	SomaScan	C5	C5a
3293-2	SomaScan	CD5L	CD5L
4496-60	SomaScan	MMP12	MMP-12
2687-2	SomaScan	MIA	MIA
3316-58	SomaScan	SERPIND1	Heparin cofactor II
3473-78	SomaScan	MPL	Thrombopoietin Receptor
2982-82	SomaScan	LGALS4	Galectin-4
3298-52	SomaScan	CNTN4	Contactin-4
3044-3	SomaScan	CCL18	PARC
<i>5107-7</i>	SomaScan	NOTCH1	Notch 1
4153-11	SomaScan	SERPINA3	alpha-1-antichymotrypsin complex
3805-16	SomaScan	ESM1	Endocan
3339-33	SomaScan	THBS2	TSP2
4160-49	SomaScan	MMP2	MMP-2
3079-62	SomaScan	RARRES2	TIG2
<i>3519-3</i>	SomaScan	CCL17	TARC
3035-80	SomaScan	IL19	IL-19
5363-51	SomaScan	SEMA3E	Semaphorin 3E
3235-50	SomaScan	WFIKKN2	WFKN2
2705-5	SomaScan	CCL25	TECK
3600-2	SomaScan	CHIT1	Chitotriosidase-1

4141-79	SomaScan	CXCL10	IP-10
3348-49	SomaScan	BMP1	BMP-1
3029-52	SomaScan	CD209	DC-SIGN
3508-78	SomaScan	CCL22	MDC
2816-50	SomaScan	BCAM	BCAM
2826-53	SomaScan	EDA	EDA
5491-12	SomaScan	SPOCK2	Testican-2
5029-3	SomaScan	FAP	SEPR
4930-21	SomaScan	STC1	Stanniocalcin-1
CRTAM	Olink Neurology	CRTAM	N/A
EZR	Olink Neurology	EZR	N/A
FcRL2	Olink Neurology	FCRL2	N/A
G.CSF	Olink Neurology	CSF3	N/A
GDF.8	Olink Neurology	MSTN	N/A
GZM A	Olink Neurology	GZMA	N/A
NEP	Olink Neurology	MME	N/A
N.CDase	Olink Neurology	ASAH2	N/A
NMNAT1	Olink Neurology	NMNAT1	N/A
NTRK3	Olink Neurology	NTRK3	N/A
SKR3	Olink Neurology	ACVRL1	N/A
SIGLEC1	Olink Neurology	SIGLEC1	N/A
SMPD1	Olink Neurology	SMPD1	N/A
CCL11	Olink Inflammatory	CCL11	N/A
CD6	Olink Inflammatory	CD6	N/A
CXCL10	Olink Inflammatory	CXCL10	N/A
CXCL11	Olink Inflammatory	CXCL11	N/A
CXCL9	Olink Inflammatory	CXCL9	N/A
EN.RAGE	Olink Inflammatory	S100A12	N/A
TGF.alpha	Olink Inflammatory	TGFA	N/A
FGF.21	Olink Inflammatory	FGF21	N/A
HGF	Olink Inflammatory	HGF	N/A
OSM	Olink Inflammatory	OSM	N/A
VEGFA	Olink Inflammatory	VEGFA	N/A
<i>MMP.1</i>	Olink Inflammatory	MMP1	N/A

Supplementary Table 3. Predictor weights for the 45 protein EpiScores included in the composite protein EpiScore.

Variable	Coefficient
GZMA	-0.1070275
N.CDase	-0.0013707
NTRK3	-0.0105284
SKR3	0.02292682
CCL11	0.01486593
CXCL11	-0.0363625
FGF.21	0.05884652
HGF	0.05611636
MMP.1	-0.0528479
2705-5	0.0411362
2851-63	0.07807877
2948-58	0.03807306
2967-8	0.08372915
3029-52	-0.0004437
3038-9	-0.0062101
3044-3	0.2568256
3060-43	-0.078839
3079-62	0.1024936
3152-57	0.01995523
3175-51	0.02976706
3291-30	0.03575731
3292-75	-0.0045541
3293-2	0.04389995
3339-33	0.04065941
3348-49	0.02393257
3403-1	-0.0070861
3448-13	0.02739967
3470-1	0.10485373
3485-28	0.05615907
3505-6	-0.0178471
3519-3	-0.0543479
3600-2	0.03783531
3617-80	0.03982561
4160-49	-0.0499596
4407-10	0.03860081

4435-66	0.01144093
4481-34	-0.0549405
4496-60	0.10710256
4763-31	0.03997106
4831-4	-0.0265954
4920-10	-8.29E-05
4924-32	0.0123399
5000-52	0.00608975
5124-69	0.00134476
5363-51	-0.0156491

Supplementary Table 4. Summary of CVD risk models based on ASSIGN. N – null model (adjusted for age + sex + ASSIGN), E – CVD EpiScore, T – cardiac troponin I

Model	HR _{age}	Page	HR _{sex}	P _{sex}	HRASSIGN	P _{ASSIGN}	HR_E	PE	HR_T	P _T	AUC	PRAUC	C-index
N	1.01	0.54	1.13	0.23	2.05	<2.2x10 ⁻¹⁶	-	-	-	-	0.719	0.198	0.712
N+E	1.00	0.99	1.05	0.64	1.94	1.10x10 ⁻¹⁶	1.3	5.6x10 ⁻³	-	-	0.723	0.201	0.715
N+T	1.00	0.83	1.04	0.71	2.02	<2.2x10 ⁻¹⁶	-	-	1.16	1.1x10 ⁻²	0.721	0.202	0.714
N+E+T	1.00	0.65	0.96	0.71	1.91	6.70x10 ⁻¹⁶	1.32	3.7x10 ⁻³	1.17	7.1x10 ⁻³	0.724	0.205	0.717

Supplementary Table 5. Summary of CVD risk models based on SCORE2. N – null model (adjusted for age + sex + ASSIGN), E – CVD EpiScore, T – cardiac troponin I

Model	HR _{age}	Page	HR _{sex}	P _{sex}	HR _{SCORE2}	P _{SCORE2}	HRE	PE	HR _T	P _T	AUC	PRAUC	C-index
N	1.02	0.05	0.96	0.75	1.79	1.8x10 ⁻¹¹	-	-	-	-	0.699	0.174	0.696
N+E	1.01	0.15	0.92	0.50	1.64	5.4x10 ⁻⁸	1.34	2.4x10 ⁻³	-	-	0.704	0.179	0.699
N+T	1.01	0.14	0.88	0.32	1.77	6.3x10 ⁻¹¹	-	-	1.18	4.8x10 ⁻³	0.701	0.175	0.698
N+E+T	1.01	0.37	0.84	0.16	1.61	1.8x10 ⁻⁷	1.36	1.4 x10 ⁻³	1.19	2.7 x10 ⁻³	0.707	0.182	0.702

Supplementary Methods

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2324

25

26

EpiScores for cardiac troponin We generated an EpiScore for cTnI. The training set consisted of Sets 2 and 3 combined, whereas Set 1 was the test set. To minimise information from shared environments and relatedness leaking between the training and test sets, any individuals in the training set associated with the same family ID as individuals from the test set were excluded from further analyses. After this step, there were 9,754 individuals in the training set and 5,003 individuals in the test set. As part of data pre-processing, all variables were trimmed of outliers (points beyond 3 SDs of the mean). The measured concentrations of cTnI underwent rank-based inverse normal transformation. Using linear mixed effects models, age, age² and sex were regressed out of the transformed variable, with a pedigree-based kinship matrix fitted as a random effect. The subsequent model residuals were saved and entered as the outcome of elastic net regression models. Methylation levels were treated as the independent variables. Elastic net models were run using biglasso (version 1.5.0) in R (version 4.0.3). The L1-L2 mixing parameter was set to alpha=0.5, and ten-fold cross-validation was applied. Non-zero coefficients/weights from the models were extracted. To calculate the EpiScore, CpG methylation values were multiplied by these coefficients and summed for each individual in the test set. The proportion of variance explained by the EpiScore was estimated by comparing R² estimates from the null and full linear regression models. Null models were adjusted for age, sex, and cTnI whereas full models accounted for age, sex, cTnI and the EpiScore.

EpiScores for 109 circulating proteins

We have previously generated 109 EpiScores for plasma protein levels ¹³. Briefly, elastic net penalised regression models were run with 953 possible protein levels as outcomes and up to 428,489 DNAm measurements from the Illumina 450k array as input features. Protein levels were adjusted for genetic effects (protein quantitative trait loci – pQTLs) prior to training EpiScores. Protein EpiScores were trained in two cohorts: the Lothian Birth Cohort of 1936 (training set contained between 725 and 875 individuals for 160 Olink inflammatory and neurology proteins) and the German cohort, KORA (944 individuals, 793 SOMAscan proteins). 109 scores (84 trained in KORA and 25 trained in the Lothian Birth Cohort 1936) explained between 1% and 58% of the variance in protein levels (with r>0.1 and P<0.05) in independent test cohorts. In this study, the 109 protein EpiScores were projected into Generation Scotland (n = 18,413) through the publicly available MethylDetectR Shiny App. Before applying weights, DNAm level at each site was scaled to have a unit SD and mean of zero. This procedure was performed separately in each set.